Evidence map›Paper›PMID 36970726›Full record

ArticleCancer research communications2022

Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor-positive Breast Cancer.

Robert B Jones, Jonathan Farhi, Miranda Adams, Kiran K Parwani, Garrett W Cooper, Milica Zecevic, Richard S Lee, Andrew L Hong, Jennifer M Spangle

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Harnessing the Role ofInternational journal of molecular sciences · 2025
    Article
  3. DynamicJournal of the American Chemical Society · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Robert B Jones *Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.ORCID 0000-0002-7886-8470
Jonathan Farhi *Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.ORCID 0000-0001-8720-496X
Miranda AdamsDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.ORCID 0000-0001-5133-2097
Kiran K ParwaniDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.ORCID 0000-0002-4316-5724
Garrett W CooperGenetics and Molecular Biology Graduate Program, Emory University School of Medicine, Atlanta, Georgia.ORCID 0000-0002-6239-8582
Milica ZecevicDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.ORCID 0000-0002-0370-6880
Richard S LeeDepartment of Biology, Emory University, Atlanta, Georgia.ORCID 0000-0003-1775-715X
Andrew L HongDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.ORCID 0000-0003-0374-1667
Jennifer M SpangleDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.ORCID 0000-0002-0181-3244
Emory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM008490 · NIGMS · EMORY UNIVERSITY · PI BOSS, JEREMY M. · 1993 to 2022
$8.0M
The PI3K/AKT Pathway Regulates Histone H3 ModificationR00CA204601 · NCI · EMORY UNIVERSITY · PI SPANGLE, JENNIFER MARIE · 2019 to 2021
$747k
NCI NIH HHS P30 CA138292NCI NIH HHS R00 CA204601NIGMS NIH HHS T32 GM008490
6 · The paper itself

Abstract

The high frequency of aberrant PI3K pathway activation in hormone receptor-positive (HR Significance: Here the authors leverage PI3K/AKT-driven chromatin modification to identify histone methyltransferases as a therapeutic target. Dual PI3K and MLL inhibition synergize to reduce clonogenicity and cell proliferation, and promote

Indexed as

Breast NeoplasmsPhosphatidylinositol 3-KinasesChromatinFemaleHistone-Lysine N-MethyltransferaseHumansProto-Oncogene Proteins c-aktRetinoblastoma-Binding Protein 2ThiazolesAlpelisibChromatinHistone-Lysine N-MethyltransferaseKDM5A protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRetinoblastoma-Binding Protein 2Thiazoles

Identifiers

PMID36970726
PMCPMC10036132
OpenAlexW4309323490

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read53
table measurements read8
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.